Humanetics To Provide New Medications For Radiation Exposure.

E-mail Print PDF


Humanetics Corporation, a major company providing accelerated development and commercialization of proprietary drugs in markets with urgent and unmet needs, announced that radiotherapy_deviceit has signed a new global license for medications that are able to reduce the effects accompanied with radiation exposure such as that occurring during CT and radiotherapy scans.

The Minneapolis-based Humanetics has signed the license of two compounds from the Henry Ford Health System in Detroit. One of these compounds is effective within 24 hours after radiation exposure while the other one remains active for more than 24 hours after exposure to radiation.

More radiation exposure medications from Humanetics.

Moreover, Humanetics has also claimed the global rights for BIO 300, which is another medication for radiation exposure that is to be used before undergoing CT scans to provide patients with protection against accidental radiation over doses. Humanetics is waiting for the approval from the US Food and Drug Administration (FDA) before being able to market its BIO300. The pill-formatted medication will offer a solution in cases of radiation exposure even in non-medical circumstances such as radiation exposure from a terrorist attack or a nuclear accident. The new medications offered by Humanetics aim to provide relatable solutions against several issues such as Acute Radiation Syndrome (ARS) and Delayed Effects of Acute Radiation Exposure (DEARE), which includes a number of diseases that start to appear months following radiation exposure, such as pneumonitis and pulmonary fibrosis.

These signals are relayed buying clomid online safe which then is by a number of such as medial preoptic and paraventricular nulcei.